查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球正壓通氣 (PAP) 設備市場
市場調查報告書
商品編碼
1140754

2022-2029 年全球正壓通氣 (PAP) 設備市場

Global Positive Airway Pressure (PAP) Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

睡眠呼吸暫停綜合徵的增加推動市場增長

睡眠呼吸暫停綜合徵是由於睡眠時呼吸受到干擾而引起的呼吸系統疾病，常見於肥胖人群和糖尿病患者。阻塞性睡眠呼吸暫停 (OSA) 是睡眠期間的部分和完全氣道阻塞。嚴重程度由呼吸暫停低通氣指數 (AHI) 計算，該指數是每小時睡眠中呼吸暫停低通氣發作的平均次數。

近年來，阻塞性睡眠呼吸暫停 (OSA) 呈上升趨勢。根據 Statista 2021 年數據，到 2028 年，全球睡眠呼吸暫停治療和診斷市場規模預計將達到 82.4 億美元。其中超過 32 億美元預計將發生在北美。該統計數據按地區顯示了自 2018 年以來全球睡眠呼吸暫停治療和診斷市場的規模，並包括到 2028 年的預測。睡眠呼吸暫停是一種醫療狀況，其中患者的呼吸模式在睡眠期間減少或停止。不健康的生活習慣增加了阻塞性睡眠呼吸暫停的患病率。成人睡眠障礙的預期患病率正在增加。因此，睡眠呼吸暫停患病率的上升預計將增加對 PAP 設備的需求。

然而，全球氣道正壓通氣 (PAP) 設備的市場增長可能會受到與 PAP 機器相關的高成本的阻礙。例如，持續氣道正壓通氣 (CPAP) 設備的平均成本在 250 美元到 1,000 美元之間，具體取決於品牌、機器型號和功能。然而，由於睡眠呼吸暫停治療由健康保險承保，患者必須承擔總費用的一部分。此外，用於旅行的新上市便攜式 CPAP 設備被視為奢侈品，不在任何保險範圍內。

區域滲透率。

北美是預測期內的主要地區。

按地區劃分，氣道正壓通氣 (PAP) 設備的全球市場分為北美、歐洲、亞太地區、拉丁美洲、中東和非洲。

由於該地區阻塞性睡眠呼吸暫停綜合徵的患病率不斷上升，北美在 2021 年佔全球氣道正壓通氣 (PAP) 設備市場的最大市場份額。例如，根據美國國家睡眠基金會的數據，到 2021 年，阻塞性睡眠呼吸暫停是美國最常見的睡眠呼吸暫停類型。據估計，它會影響美國 10% 至 30% 的面臨阻塞性睡眠呼吸暫停的成年人，但它通常仍未得到診斷。PAP 設備的需求量很大，因為它們具有調節壓力的能力，並且可以根據患者的需求和睡眠階段進行自動調整。此外，美國保險公司提供的優惠報銷政策有力地支持了該地區 PAP 設備的增長。這導致更多的患者選擇治療睡眠呼吸暫停，並顯著增加了 PAP 設備的採用。糖尿病和肥胖症患病率的上升也有望刺激市場增長。

亞太地區睡眠呼吸暫停發病率高，日本循環學會、中國睡眠學會等政府主導的支持力度加大，以提高該地區對睡眠呼吸暫停的認識，預計增長最快預測期內的利率。此外，中國、日本和印度的產品發布、批准和與國際公司的合作夥伴關係都在增加。

競爭格局。

氣道正壓通氣 (PAP) 設備市場的主要參與者包括 Koninklijke Philips NV (Philips Respironics)、ResMed、Fisher and Paykel Healthcare Limited、DeVilbiss Healthcare Inc 和 Smiths Medical、3B Medical。領先的公司正在採取多種增長戰略，例如產品發布、收購和合作夥伴關係，為全球氣道正壓通氣 (PAP) 設備市場的增長做出了貢獻。2022年1月，ICU Medical完成了對Smiths Group plc的Smiths Medical的收購。此次收購已與 ICU Medical 的現有業務整合。合併後的公司創建了一家領先的輸液治療公司，預計綜合收入約為 25 億美元。2021年12月，全球醫療技術領導者菲利普收購美國醫療技術公司Vesper Medical，以擴大其影像引導治療設備產品組合。Vesper Medical 計劃通過其用於治療深靜脈疾病的先進靜脈支架產品組合進一步擴展飛利浦的診斷和治療設備產品組合。此次收購有助於擴大血管治療領域。2021 年 6 月，Phillips在美國召回了 Bi-Level PAP、CPAP 和機械呼吸機。2022年5月，全球醫療技術領導者Medtronic完成了對Intersect ENT的收購。此次收購擴大了公司全面的耳鼻喉 (ENT) 產品組合，包括改善術後結果和治療用於鼻竇手術的鼻息肉等創新產品。

COVID-19 的影響會對氣道正壓通氣 (PAP) 設備產生積極影響。

COVID-19 正在影響全球經濟，直接影響生產和需求、供應鏈中斷和市場中斷，以及對企業和金融市場的財務影響。

由於 COVID-19 大流行的危機，在 FDA 最近的緊急政策之後，持續氣道正壓通氣 (CPAP) 作為救生呼吸機的替代品開始獲得更多的認可。隨著 COVID-19 疫情的發展，全球呼吸機價格居高不下，表明嚴重短缺。2020 年 6 月，研發和製造持續氣道正壓通氣 (CPAP) 的醫療器械公司 Apex Medical Corp. 推出了 CPAP 產品和新設計的導管的集成解決方案，用於治療輕度和中度 COVID。-19 名患者將獲得另一個呼吸治療方案。

目錄

第一章 調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第二章市場定義和概述

第三章執行摘要

  • 按類型劃分的市場細分
  • 最終用戶的市場細分
  • 區域市場細分

第四章市場動態

  • 市場影響因素
  • 促進者
    • 裝置技術進步
  • 抑製劑
    • 嚴格的監管審批
  • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 中的價格動態
  • 供需譜
  • 大流行期間與市場相關的政府努力
  • 製造商的戰略舉措
  • 概括

第 7 章 按類型

  • 自動氣道正壓通氣 (APAP) 裝置
  • 雙水平氣道正壓通氣 (BiPAP) 裝置
  • 持續氣道正壓通氣 (CPAP) 機

第 8 章最終用戶

  • 醫院
  • 睡眠研究所
  • 家庭醫療
  • 其他

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東/非洲

第 10 章 競爭格局

  • 競爭情景
  • 市場/份額分析
  • 併購分析

第十一章公司簡介

  • Smiths Medical
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務概覽
  • Koninklijke Philips N.V.
  • Devilbiss Healthcare LLC
  • Medtronic Plc.
  • Draegerwerk AG & Co. KGaA
  • 3B Medical, Inc.
  • ResMed Inc.
  • Fisher & Paykel Healthcare Limited
  • Lowenstein Medical UK Ltd.
  • APEX MEDICAL CORP.（List Not Exhaustive）

第 12 章 數據管理

簡介目錄
Product Code: DMPH2858

Market Overview

Positive Airway Pressure (PAP) Devices Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 4.5 % during the forecast period (2022-2029).

Positive airway pressure (PAP), such as continuous PAP (CPAP) or bilevel PAP (BPAP), is used to treat breathing disordered during sleep, such as Obstructive Sleep Apnea (OSA), Central Sleep Apnea (CSA) or hypoventilation (as may be seen in patients with Obesity Hypoventilation Syndrome, COPD, or neuromuscular diseases). The global positive airway pressure (PAP) Devices market growth is driven by factors such as the rising prevalence of sleep apnea, rising collaborations, and increasing R&D investments toward developing technologically-advanced devices.

Market Dynamics: Rising prevalence of sleep apnea is driving the market growth

Sleep Apnea is a respiratory disorder caused due to disruption of breathing during sleeping commonly observed in obese people and diabetes patients, resulting in loud snoring due to blockage of air during breathing. Obstructive sleep apnea (OSA) is the partial and complete airway obstructions that occur while sleeping. The severity of the disease is calculated with an apnea-hypopnea index (AHI which is the mean number of apneas and hypopneas per hour of sleep.

Obstructive sleep apnea (OSA) has increased over the past few years. According to Statista data 2021, the total global market size for sleep apnea therapeutics and diagnostics was expected to reach 8.24 billion U.S. dollars by 2028. Over 3.2 billion dollars was forecast to be generated in North America. This statistic represents the sleep apnea therapeutics and diagnostics market size worldwide by region since 2018, with projections up to 2028. Sleep apnea is a medical condition in which the patient's breathing patterns during sleep decrease or even stop. The prevalence of obstructive sleep apnea is growing due to an unhealthy lifestyle. The anticipated prevalence of sleep-disordered disorders has grown in adults. Hence, the rising prevalence of sleep apnea is anticipated to rise the demand for PAP devices.

However, the global positive airway pressure (PAP) Devices market growth is likely to be hampered by the high cost associated with PAP machines. For instance, the average cost of continuous positive airway pressure (CPAP) device varies between $250 to $1,000, depending on the brand, machine model, and feature. However, health insurance covers the cost of sleep apnea treatment; patients must bear some part of the total cost. Also, the portable travel-friendly CPAP devices newly launched in the market are considered merely luxury items and are not covered by any insurance coverage.

Market Segmentation: The CPAP Segment is projected to be the dominant segment in the market during the forecast period.

Based on product type, the global market for PAP devices is classified into Automatic Positive Airway Pressure (APAP) Devices, Bilevel Positive Airway Pressure (BiPAP) Devices, and Continuous Positive Airway Pressure (CPAP) Devices.

The CPAP devices accounted for the largest market share and are anticipated to grow significantly over the forecast period. Continuous Positive Airway Pressure (CPAP) Devices are the first line of treatment for obstructive sleep apnea. They are prescribed to a patient suffering from snoring and episodes of obstructed breathing during sleep. In addition, increased adoption of these devices due to their low cost compared to other PAP devices has supported the growth of this segment.

On the other hand, the Bilevel Positive Airway Pressure (BiPAP) devices segment is expected to grow at the fastest rate over the forecast period. This device is recommended for patients with difficulty exhaling while using a CPAP device. The device has an advantage over CPAP devices, which is more efficient in the breathing pattern of patients as it provides an alternate/variable flow of air. Also, the accessibility of reasonable reimbursement and the availability of technologically advanced products are some of the key factors expected to drive the growth of this segment over the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

In terms of region, the global Positive Airway Pressure (PAP) Devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America accounted for the largest market share of the global positive airway pressure (PAP) devices market in 2021, owing to the rising prevalence of obstructive sleep apnea in this region. For instance, according to National Sleep Foundation in 2021, in the U.S, Obstructive sleep apnea is the most common type of sleep apnea. It is estimated to affect 10% to 30% of adults in the United States facing obstructive sleep apnea but, in many cases, goes undiagnosed. There is high demand for PAP devices as they have the facility of adjusting pressure, and auto adjustments can be made based on the patient's need and sleep stage. Moreover, favorable reimbursement policies offered by insurance providers in the U.S. have strongly supported the growth of PAP devices in this region. This, in turn, has encouraged the patients to opt for sleep apnea treatment, which has led to a significant increase in the adoption of PAP devices. Besides, the growing prevalence of diabetes and obesity is likely to fuel market growth.

The Asia Pacific is expected to grow at the fastest growth rate over the forecast period due to the high prevalence of sleep apnea diseases and increasing support from government initiatives, like the Japanese Circulation Society and Chinese Sleep Research Society, to create awareness of sleep apnea disorders in this region. In addition, increasing product launches, approvals, and collaborations by international players in China, Japan and India.

Competitive Landscape:

Some of the major players in the positive airway pressure (PAP) devices market include Koninklijke Philips N.V. (Philips Respironics), ResMed, Fisher and Paykel Healthcare Limited, DeVilbiss Healthcare Inc., and Smiths Medical, 3B Medical, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the global positive airway pressure (PAP) devices market. In January 2022, ICU Medical completed the acquisition of Smiths Medical from Smiths Group plc. Through this acquisition, they combined with ICU Medical's existing businesses; the combined companies created a leading infusion therapy company with estimated pro forma combined revenues of approximately $2.5 billion. In December 2021, Philip, a global leader in health technology, expanded its image-guided therapy devices portfolio by acquiring Vesper Medical, a US-based medical technology company. Vesper Medical will further expand Philips' portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for treating deep venous disease. This acquisition helped expand the vascular therapy space. In June 2021, Philips recalled Bi-Level PAP, CPAP, and mechanical ventilator devices in the United States. In May 2022, Medtronic, a global leader in healthcare technology, completed the acquisition of Intersect ENT. This acquisition helps to expand the company's comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve postoperative outcomes and treat nasal polyps.

COVID-19 Impact: Positive impact on the positive airway pressure (PAP) devices.

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Due to the COVID-19 pandemic crisis, continuous positive airway pressure (CPAP) has started witnessing greater preference as a potential replacement for lifesaving ventilators after the FDA's recent emergency policy. As the COVID-19 pandemic continues to develop, the global price of ventilators is high and seriously inadequate. In June 2020, Apex Medical Corp., the medical device company, who develops and manufactures the continuous positive airway pressure machine (CPAP), has launched the integrated solution of its CPAP product with the new catheter design to provide mild and moderate COVID-19 patients with another respiratory treatment program.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by End-User
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Technological Advancements In Devices
    • 4.2.2. XX
  • 4.3. Restraints
    • 4.3.1. Stringent regulatory approvals
    • 4.3.2. XX
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Automatic Positive Airway Pressure (APAP) Devices*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Bilevel Positive Airway Pressure (BiPAP) Devices
  • 7.4. Continuous Positive Airway Pressure (CPAP) Devices

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User Segment
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Sleep Laboratories
  • 8.4. Home Care
  • 8.5. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Smiths Medical*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Koninklijke Philips N.V.
  • 11.3. Devilbiss Healthcare LLC
  • 11.4. Medtronic Plc.
  • 11.5. Draegerwerk AG & Co. KGaA
  • 11.6. 3B Medical, Inc.
  • 11.7. ResMed Inc.
  • 11.8. Fisher & Paykel Healthcare Limited
  • 11.9. Lowenstein Medical UK Ltd.
  • 11.10. APEX MEDICAL CORP. (List Not Exhaustive)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us